Abstract：Objective To investigate the clinical effect and safety of anti-D immunoglobulin (anti-D) in the treatment of children with newly diagnosed acute immune thrombocytopenia (ITP) through a Meta analysis. Methods PubMed, EMBASE, Cohrane Library, Ovid, CNKI, and Wanfang Data were searched for randomized controlled trials (RCTs) published up to April 2017. Review Manager 5.3 was used for the Meta analysis. Results Seven RCTs were included. The Meta analysis showed that after 72 hours and 7 days of treatment, the intravenous immunoglobulin (IVIG) group had a significantly higher percentage of children who achieved platelet count > 20×109/L than the anti-D group (P < 0.05). There were no significant differences in platelet count after 24 hours, 72 hours, and 7 days of treatment between the anti-D (50 μg/kg) group and the IVIG group (P > 0.05), and there were also no significant differences in platelet count after 24 hours and 7 days of treatment between the 50 μg/kg and 75 μg/kg anti-D groups (P > 0.05). The anti-D group had a significantly greater reduction in the hemoglobin level than the IVIG group after treatment, but did not need transfusion. No children in the anti-D group or the IVIG group experienced serious adverse reactions. Conclusions Intravenous injection of anti-D may have a similar effect as IVIG in improving platelet count in children with acute ITP, but it may be slightly inferior to IVIG in the rate of platelet increase after treatment. The anti-D dose of 50 μg/kg may have a similar effect as 75 μg/kg. The recommended dose of anti-D for treatment of ITP is safe.
Cheung E, Liebman HA. Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia[J]. Biologics, 2009, 3:57-62.
[3]
Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia[J]. Blood, 2011, 117(16):4190-4207.
Son DW, Jeon IS, Yang SW, et al. A single dose of anti-D immunoglobulin raises platelet count as efficiently as intravenous immunoglobulin in newly diagnosed immune thrombocytopenic purpura in Korean children[J]. J Pediatr Hematol Oncol, 2008, 30(8):598-601.
[6]
Shahgholi E, Vosough P, Sotoudeh K, et al. Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura[J]. Indian J Pediatr, 2008, 75(12):1231-1235.
[7]
Papagianni A, Economou M, Tragiannidis A, et al. Standard-dose intravenous anti-D immunoglobulin versus intravenous immunoglobulin in the treatment of newly diagnosed childhood primary immune thrombocytopenia[J]. Pediatr Hematol Oncol, 2011, 33(4):265-269.
[8]
Celik M, Bulbul A, Aydogan G, et al. Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura[J]. J Thromb Thrombolysis, 2013, 35(2):228-233.
[9]
Alioglu B, Ercan S, Tapci AE, et al. A comparison of intravenous immunoglobulin(2 g/kg totally) and single doses of anti-D immunoglobulin at 50 μg/kg, 75 μg/kg in newly diagnosed children with idiopathic thrombocytopenic purpura:Ankara hospital experience[J]. Blood Coagul Fibrinolysis, 2013, 24(5):505-509.
[10]
Tarantino MD, Young G, Bertolone SJ, et al. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children[J]. J Pediatr, 2006, 148(4):489-494.
[11]
Blanchette V, Imbach P, Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura[J]. Lancet, 1994, 344(8924):703-707.
[12]
Swain TR, Jena RK, Swain KP. High dose intravenous anti-D immune globulin is more effective and safe in Indian paediatric patients of immune thrombocytopenic purpura[J]. J Clin Diagn Res, 2016, 10(12):FC12-FC15.
[13]
Cooper N. Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia[J]. Hematol Oncol Clin North Am, 2009, 23(6):1317-1327.
